Study of CM355 in Patients With Systemic Lupus Erythematosus
- Sponsor
- Second Xiangya Hospital of Central South University
- Study ID
- NCT07104344
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- CM355 — BIOLOGICALCM355 injection
Study Details
This study was designed to investigate the safety and efficacy of CM355 in patients with refractory SLE.
Key Dates
- First listed
- Aug 5, 2025
- Start date
- Sep 25, 2025
- Status verified
- Jul 2025
- Primary completion
- Apr 30, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 5 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CM355
Primary Outcome Measure
adverse events (AE) [ Time Frame: Throughout the study，an average of about 1 year ]
Central Contacts
- Qianjin Lu+86 13787097676
Find similar trials
Related Studies
- Study of Systemic Lupus ErythematosusRecruiting · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Bethesda, Maryland
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)Recruiting · Hospital for Special Surgery, New York · New York, New York
- Duke Lupus RegistryRecruiting · Duke University · Durham, North Carolina
- Systemic Lupus Erythematosus in Gullah HealthRecruiting · Medical University of South Carolina · Charleston, South Carolina